Merck & Co., Inc. (NYSE:MRK) is included in our list of the best stocks to buy for financial stability. Merck & Co. (NYSE) to Acquire Terns Pharma for $6.7 Billion On March 25, 2026, Merck & Co., Inc. (NYSE:MRK) came into the limelight when Reuters reported that the company had agreed to buy Terns Pharma for $6.7 billion. The move comes as the company looks to expand its cancer pipeline amid concerns surrounding the looming patent loss for blockbuster therapy Keytruda. By the end of this decade, Merck ...

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient- reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study Late-breaking results also published in Arthritis & Rheumatology INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in ...

Incyte's skin disease drug shows long-term symptom relief in late-stage trials | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Companies Incyte Corp Follow Abbvie Inc Follow Novartis AG Follow Show more companies Povorcitinib is a once-daily pill that works by blocking JAK1, a protein involved in the inflammation that leads to painful abscesses and nodules. Treatment options for the condition are limited and are mainly injectable drugs. There are curr ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care. ...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpointsData reinforce potential for Q12W dosing from the start Paris, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, a fully human non-T cell depleting monoclonal antibody t ...

Stock Market Week Ahead: Scarcity Narratives And Naval Tactics| Investor's Business Daily BREAKING: Major Indexes Fall For Fifth Straight Week Stock market investors don't like leaving money on the table heading into weekends lately. That showed clearly on Thursday and Friday, when the Nasdaq and S&P 500 posted a 'cut and run' finish to the week. The result left both dangling at their lowest levels since August. Neither showed any sign of beginning to form a bottom. All three major indexes are now mo ...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia (HTG). The data were presented by Dr. Christie M. Ballantyne, MD, professor at Baylor College of Medicine, member of the Texas Heart Institute at Baylor, and Principal Inve. ...

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

ICOTYDE achieved high levels of complete skin clearance up to Week 52 with no new safety signals2,a "Introducing a oncedaily targeted oral peptide for treating moderatetosevere plaque psoriasis offers patients an option with a unique combination of benefits and a favorable safety profile," said Linda Stein Gold, M.D., Director of Dermatology Clinical Research at Henry Ford Health and ICONICADVANCE study investigator.c "The results from oneyear studies show encouraging outcomes for patients as they navigate ...

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 - 24/7 Wall St. S&P 5006,362.40 -2.11% Nikkei 22551,507.00 -2.23% Investing PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 By Michael WilliamsPublished Mar 28, 7:15AM EDT Quick Read VanEck Pharmaceutical ETF (PPH) is 17.91% concentrated in Eli Lilly (LLY), which has fallen 16% year-to- date as generic GLP-1 competition and patent expirations in emerging markets threaten ...